← board
ENTX
Entera Bio Ltd.distress 5/10 · elevated risk$2.00-1%today-36% from 52w high
Lead: postmenopausal osteoporosis
Revenue
pre-revenue
Liquidity
$4M
Runway
0.5 yrs
Shares 1y
+8%
Price & events
+26.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+0.0%
1W
+29.0%
1M
+70.9%
3M
+25.0%
6M
+3.6%
1Y
+11.1%
2Y
-62.3%
5Y
+61.3%
All
Overview
- Market Cap
- $98.45M
- Volume
- 1.93K
- 52 Week Range
- $1.00 – $3.14
- Total Shares
- 49.23M
- Float Shares
- 40.37M
- Short %
- 0.78%
- % Held by Insiders
- 23.10%
- % Held by Institutions
- 15.98%
- RVOL
- 0.00x
- Beta
- 1.43
Pipeline stages · 1 programs
EBP05, Forteo 0.02 mg, EBP11
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-02-08 | Phase 1 | EBP05, Forteo 0.02 mg, EBP11 | Hypoparathyroidism, Osteoporosis, Fractures, Bone, Other Disease | 45 | completed |
Catalyst news & presentations · 5
- 2026-03-04regulatory submissionFiled (NDA/BLA)EB613 · Submitted Phase 3 protocol to FDA to initiate registrational trialSEC 8-K
- 2026-02-03partnershipLA-PTH · Amended collaboration with OPKO to co-develop daily long-acting PTH tablet for hypoparathyroidism.SEC 8-K
- 2025-07-28fda agreementEB613 · FDA agreed BMD can be primary endpoint for Phase 3 studySEC 8-K
- 2025-06-12fda agreementEB613 · FDA agreed DART studies not requiredSEC 8-K
- 2025-03-16partnershipGLP-1/glucagon agonist (OPK-88006) · Entera Bio and OPKO Health entered into collaboration and license agreement for oral delivery of dual agonist using N-Tab technology.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+350% upside) · 1 analysts
- 2026-04-27HC Wainwright & Co.Buy
- 2026-02-09HC Wainwright & Co.Buy
- 2025-03-18HC Wainwright & Co.Buy
- 2024-11-11HC Wainwright & Co.Buy
- 2024-10-07HC Wainwright & Co.Buy
- 2024-09-27HC Wainwright & Co.Buy
Competitors — postmenopausal osteoporosis
- none identified
Recent news
- 2026-07-22Entera Bio Leads Our Top 3 Penny Stocks To Consider - simplywall.st
- 2026-07-22Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-21Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know - Yahoo Finance Singapore
- 2026-07-17Entera Bio Ltd. Approves Director Compensation, Share-Based Plans, and Capital Increase at 2026 Annual Meeting - Minichart
- 2026-07-16Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
- 2026-07-16Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs - Stock Titan
- 2026-07-15After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - TipRanks
- 2026-07-15After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - Benzinga
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.